However, the toxicity of Bu-Mel is severe with specific endothelial toxicity and a high rate of hepatic veno-occlusive disease (VOD), non-infectious interstitial pneumonitis or pulmonary hypertension. Reducing the incidence of these complications remains a major issue for the future strategy for administering this regimen. Preclinical and clinical studies suggest that the order of administering alkylating agents can influence the toxicity of HDC. When Bu is given first in combination with another alkylating agent, it can increase the toxicity of the second drug by inducing glutathione depletion and/or lower the metabolism of the second chemotherapeutic agent. 7, 8 Based on these pharmacological data, patients o 20 years old at diagnosis of a high-risk neuroblastoma or Ewing sarcoma, not included in ongoing protocols, have been treated with the Mel-Bu combination with Mel administered before Bu since 2002 in the Gustave Roussy Pediatrics Department. The primary aim of the present study was to perform an exposed (Mel-Bu order, that is, new order) -unexposed (Bu-Mel order, that is, classic order) study in order to evaluate and compare toxicity VOD in two groups of patients. We also evaluated and compared the efficacy (EFS), a secondary aim, to determine the potential benefit of changing the order of administration of the two alkylating agents in future protocols.
Bu-Mel patients received either oral (before 2003) or IV (after 2003) Bu for 4 days followed by one dose of IV Mel 24 h after the last dose of Bu, whereas Mel-Bu patients received Mel followed by Bu. ASCT was performed 24-48 h after the last dose of chemotherapy. Supportive care was comparable to IV granulocyte colony stimulating factor (5 μg/kg per day) administered from day 5 after ASCT to the end of neutropenia. The definition of VOD fulfilled the Seattle criteria and its severity was graded according to the Bearman toxicity score. Overall survival (OS) was the time from study entry (that is, the first day of HDC) to death or the last follow-up, whichever occurred first. EFS was the time from study entry to disease progression, a second malignancy, death or the last follow-up, whichever occurred first. OS and EFS were estimated using the Kaplan-Meier method. Patients from the two treatment groups (Bu-Mel and Mel-Bu) of the same age at diagnosis were matched. The association of the treatment group with toxicity and efficacy outcomes was assessed using Cox regression models stratified on matched pairs and adjusted for other confounding factors, such as the year of diagnosis, VOD prophylaxis and age at diagnosis. VOD occurred in 16 Mel-Bu and 10 Bu-Mel patients, mostly grade II disease (11 and 6 patients, respectively). The 4-week incidence of grade II/III VOD was 31% (95% confidence interval (CI): 19-45%) and 17% (95% CI: 8-33%) for Mel-Bu and Bu-Mel patients, respectively (Figure 1a) . Before 3 months after ASCT, one patient in the Mel-Bu group experienced non-infectious interstitial pneumonitis and one patient in the Bu-Mel group developed infrasystemic pulmonary hypertension with a favorable outcome. One patient in the Mel-Bu group died of acute respiratory distress syndrome after surgical resection of the tumor, 34 days after ASCT. In the multivariate analysis, no significant difference in the risk of grade II/III VOD was observed between the two groups (hazards ratio = 2.1 (95% CI: 0.8-5.9), P-value = 0.14). No significant difference was found between the two groups in other toxicities such as digestive or hematological toxicity or even infectious complications (data not shown). Two toxic deaths occurred only in the Mel-Bu group after resection of an abdominal neuroblastoma. In addition, no difference in toxicity was observed between neuroblastoma and Ewing sarcoma (hazards ratio = 1.2 (95% CI: 0.4-3.5), P-value = 0.8).
The median follow-up was 40.6 (95% CI: 23.0-47.1) and 52.6 months (95% CI: 24.2-60.6) for Mel-Bu and Bu-Mel patients, respectively. Regarding the two efficacy outcomes, 3-year EFS ( Figure 1b ) and 3-year OS (Figure 1c) were, respectively, 61% (95% CI: 44-76%) and 69% (95% CI: 52-83%) for the Mel-Bu patients, and 55% (95% CI: 37-72%) and 65% (95% CI: 46-81%) for the Bu-Mel patients. In the multivariate analysis, no significant difference in the two efficacy outcomes was observed between the two groups: EFS (hazards ratio = 1.1 (95% CI: 0.4-3.1), P-value = 0.9) and OS (hazards ratio = 1.2 (95% CI: 0.3-4.0), P-value = 0.8). In addition, no difference in EFS was observed between neuroblastoma and Ewing sarcoma (hazards ratio = 1.5 (95% CI: 0.5-5.2), P-value = 0.5).
The morbidity of the Bu-Mel combination, mainly related to the high incidence of diffuse endothelial injury and especially hepatic VOD, remains a major concern. 9 The impact on toxicity of the order of administering alkylating agents was demonstrated with the Bu-Cy regimen commonly administered before allogeneic transplantation. Cyclophosphamide pharmacokinetics were compared in the Bu-Cy and Cy-TBI combinations. Higher exposure to cyclophosphamide and its toxic metabolite, 4-hydroxy cyclophosphamide (4OHCY) was demonstrated in the Bu-Cy combination than in its Cy-TBI counterpart. The incidence of VOD with the Bu-Cy regimen could be explained by enhanced exposure to 4OHCY. 7 An interval of o 24 h between Bu and cyclophosphamide administration caused lower cyclophosphamide clearance and a higher incidence of VOD. The administration of Bu induces glutathione depletion and inhibition of hepatic cytochrome activity leading to an increase in 4OHCY. 10, 11 Preclinical studies compared the myeloablative and immunosuppressive effects of Bu-Cy and Cy-Bu in mice. Hepatic toxicity was significantly lower in the Cy-Bu group with faster bone marrow engraftment. 12 The lower liver toxicity of Cy-Bu was confirmed, with no impact on long-term engraftment in the same mouse model. 13 In two clinical studies comparing patients receiving Bu-Cy or Cy-Bu before allogeneic or autologous transplantation for hematological malignancies, hepatic toxicity was lower in the Cy-Bu group with no impact on engraftment, survival or relapse. 8, 14 A pharmacodynamic study of Bu was conducted in pediatric patients with a solid tumor receiving Bu-containing HDC. The incidence of VOD in the Bu-Mel group was not correlated with systemic exposure to Bu unlike that observed in the Bu-Thiotepa group. This finding supported the impact of Mel on the incidence of VOD observed. The hypothesis was that the glutathione depletion induced when Bu is metabolized by glutathione-S-transferase could sensitize the liver to Mel. 15 Contrary to the results expected and previous data with the Bu-Cy combination, no significant difference was observed in terms of liver toxicity, hepatic VOD, hematological toxicity, digestive and mucosal toxicity, infectious complications and EFS. Changing the order of drug administration in the Bu-Mel combination (Mel-Bu) did not reduce toxicity. Conversely, a slight increase in the incidence of grade II/III VOD was observed by changing the order of drug administration (4-week incidence: 31% and 17% for the Mel-Bu and Bu-Mel patients, respectively). However, no clear conclusion can be drawn due to the small number of patients. These considerations need to be explored through pharmacokinetic studies in Bu-Mel and Mel-Bu patients. Pharmacokinetic studies of both Bu and Mel are required to elucidate the mechanisms of interaction between these two alkylating agents.
In conclusion, we failed to identify any benefit in changing the order of administration of Bu and Mel to decrease the toxicity of this effective high-dose regimen. However, a better understanding of the interactions of these two drugs will help to define preventive strategies enabling the safe use of this HDC in a larger number of patients. Figure 1 . Incidence of grade II/III VOD (a), EFS (b) and OS (c) for the two HDC combinations. Bu-Mel = busulfan followed by melphalan combination; Mel-Bu = melphalan followed by busulfan combination.
